Open AccessPreoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide 1
Author(s) -
HUANG Maotao,
CHEN Zhixin,
WEI Bing,
ZHANG Bo,
WANG Chunhui,
HUANG Minghui,
LIU Rui,
TANG Chengwei
Publication year - 2007
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2007.00652.x
Subject(s) - celecoxib , octreotide , medicine , somatostatin , apoptosis , tunel assay , adenocarcinoma , cancer , immunohistochemistry , cancer research , endocrinology , pharmacology , chemistry , biochemistry
Aim: To gain insight into the histopathological responses and molecular targets in the inhibition of growth of human gastric cancer treated with celecoxib (a cyclooxygenase [COX]‐2 inhibitor) combined with octreotide. Methods: Seventy five patients with gastric cancer undergoing curative gastrectomy or extended resection were randomly divided into 3 groups. The apoptosis of tumor cells was measured by terminal deoxynucleotide transferase‐mediated dUTP nick end‐labeling (TUNEL) assay. Gastric cancer microvessel density (MVD) and the expression of COX‐2 were evaluated by immunohistochemical staining. The expression of somatostatin receptor (SSTR)‐2 was detected with the biomolecular interaction analysis system. The transcription of non‐steroidal anti‐inflammatory drug‐activated gene (NAG)‐1 was measured by RT‐PCR. Results: Compared with the control and celecoxib groups, more necrosis in the combination group was observed. The apoptotic rate in the combination group (7.06%±0.67%) was significantly higher than that in the control group (6.23%±1.29%, P <0.05). The MVD decreased considerably in the combination group. The upregulation of NAG‐1 was displayed both in the celecoxib and combination groups. The positive rate of SSTR‐2 in gastric cancers treated with celecoxib (48%) was significantly higher than that of control group (12%) after surgery ( P <0.05). Conclusion: Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarci‐noma through the induction of apoptosis and the reduction of MVD. NAG‐1 and SSTR‐2 might be the molecular targets for celecoxib or octreotide.